Acorda Therapeutics, Inc. (NASDAQ:ACOR) has a beta value of 1.57 and has seen 1,578,836 shares traded in the last trading session. The company, currently valued at $35.71 Million, closed the last trade at $0.7441 per share which meant it lost $0 on the day or -0.79% during that session. The ACOR stock price is -985.88% off its 52-week high price of $8.08 and 5.93% above the 52-week low of $0.7. If we look at the company’s 10-day average daily trading volume, we find that it stood at 2.44 Million shares traded. The 3-month trading volume is 2.03 Million shares.

The consensus among analysts is that Acorda Therapeutics, Inc. (ACOR) is a Hold stock at the moment, with a recommendation rating of 3.1. 2 analysts rate the stock as a Sell, while none rate it as Overweight. 4 out of 7 have rated it as a Hold, with 1 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is -$0.48.

Acorda Therapeutics, Inc. (NASDAQ:ACOR) trade information

Despite being -0.79% in the red today, the stock has traded in the green over the last five days, with the highest price hit on Tuesday, Jun 23 when the ACOR stock price touched $0.848 or saw a rise of 12.25%. Year-to-date, Acorda Therapeutics, Inc. shares have moved -63.52%, while the 5-day performance has seen it change -9.26%. Over the past 30 days, the shares of Acorda Therapeutics, Inc. (NASDAQ:ACOR) have changed -0.47%. Short interest in the company has seen 10.39 Million shares shorted with days to cover at 5.12.

Wall Street analysts have a consensus price target for the stock at $3.33, which means that the shares’ value could jump 347.52% from current levels. The projected low price target is $1 while the price target rests at a high of $10. In that case, then, we find that the current price level is +1243.91% off the targeted high while a plunge would see the stock lose 34.39% from current levels.

Acorda Therapeutics, Inc. (ACOR) estimates and forecasts

Figures show that Acorda Therapeutics, Inc. shares have underperformed across the wider relevant industry. The company’s shares have lost -71.6% over the past 6 months, with this year growth rate of -20.93%, compared to 9.2% for the industry. Other than that, the company has, however, increased its growth outlook for the 2020 fiscal year revenue. Growth estimates for the current quarter are 12.7% and 17.4% for the next quarter. Revenue growth from the last financial year stood is estimated to be -38%.

7 analysts offering their estimates for the company have set an average revenue estimate of $28.41 Million for the current quarter. 7 have an estimated revenue figure of $31.45 Million for the next quarter concluding in September 01, 2020. Year-ago sales stood $50.05 Million and $44.72 Million respectively for this quarter and the next, and analysts expect sales will grow by -43.2% for the current quarter and -29.7% for the next.

If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was +16.45% over the past 5 years. Earnings growth for 2020 is a modest -7.6% while over the next 5 years, the company’s earnings are expected to increase by 29%.

Acorda Therapeutics, Inc. (NASDAQ:ACOR)’s Major holders

Insiders own 1.49% of the company shares, while shares held by institutions stand at 116.94% with a share float percentage of 118.71%. Investors are also buoyed by the number of investors in a company, with Acorda Therapeutics, Inc. having a total of 162 institutions that hold shares in the company. The top two institutional holders are Blackrock Inc. with over 7.32 Million shares worth more than $6.83 Million. As of March 30, 2020, Blackrock Inc. held 15.26% of shares outstanding.

The other major institutional holder is FMR, LLC, with the holding of over 5.19 Million shares as of March 30, 2020. The firm’s total holdings are worth over $4.84 Million and represent 10.82% of shares outstanding.

Also the top two Mutual Funds that are holding company’s shares are iShares Core S&P Smallcap ETF and Fidelity Select Portfolios – Biotechnology. As of March 30, 2020, the former fund manager holds about 6.44% shares in the company for having 3092252 shares of worth $2.88 Million while later fund manager owns 2.61 Million shares of worth $2.43 Million as of March 30, 2020, which makes it owner of about 5.43% of company’s outstanding stock.